Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- SourceOne Announces Start of Clinical Trial for Sytrinol(TM) and Plant Sterol Combination
Double-blind, placebo-controlled, randomized study will include several arms with a combination of Sytrinol™ and plant sterols, and will be conducted by Radiant Research Incorporated located in Chicago IL.
- SourceOne Announces Start of Clinical Trial for Sytrinol(TM) and Plant Sterol Combination
Double-blind, placebo-controlled, randomized study will include several arms with a combination of Sytrinol™ and plant sterols, and will be conducted by Radiant Research Incorporated located in Chicago IL.
- Research Shows Product Shortens Duration of Common Cold
Randomized, double-blind, placebo-controlled, multi-center study presented at the First International Conference on Natural Products and Molecular Therapy indicates that UMCKA(R) COLDCARE(TM), a proprietary medicine made from Pelargonium sidoides roots, significantly shortens duration and reduces severity of the common cold.
- Research Shows Product Shortens Duration of Common Cold
Randomized, double-blind, placebo-controlled, multi-center study presented at the First International Conference on Natural Products and Molecular Therapy indicates that UMCKA(R) COLDCARE(TM), a proprietary medicine made from Pelargonium sidoides roots, significantly shortens duration and reduces severity of the common cold.
- Research Shows Product Shortens Duration of Common Cold
Randomized, double-blind, placebo-controlled, multi-center study presented at the First International Conference on Natural Products and Molecular Therapy indicates that UMCKA(R) COLDCARE(TM), a proprietary medicine made from Pelargonium sidoides roots, significantly shortens duration and reduces severity of the common cold.
- Research Shows Product Shortens Duration of Common Cold
Randomized, double-blind, placebo-controlled, multi-center study presented at the First International Conference on Natural Products and Molecular Therapy indicates that UMCKA(R) COLDCARE(TM), a proprietary medicine made from Pelargonium sidoides roots, significantly shortens duration and reduces severity of the common cold.
- Research Shows Product Shortens Duration of Common Cold
Randomized, double-blind, placebo-controlled, multi-center study presented at the First International Conference on Natural Products and Molecular Therapy indicates that UMCKA(R) COLDCARE(TM), a proprietary medicine made from Pelargonium sidoides roots, significantly shortens duration and reduces severity of the common cold.
- Research Shows Product Shortens Duration of Common Cold
Randomized, double-blind, placebo-controlled, multi-center study presented at the First International Conference on Natural Products and Molecular Therapy indicates that UMCKA(R) COLDCARE(TM), a proprietary medicine made from Pelargonium sidoides roots, significantly shortens duration and reduces severity of the common cold.
- Research Shows Product Shortens Duration of Common Cold
Randomized, double-blind, placebo-controlled, multi-center study presented at the First International Conference on Natural Products and Molecular Therapy indicates that UMCKA(R) COLDCARE(TM), a proprietary medicine made from Pelargonium sidoides roots, significantly shortens duration and reduces severity of the common cold.
- Calcium and Vitamin D Most Effective for Treatment of Crohn's-related Bone Loss
Study shows that calcium and vitamin D treatment alone can improve bone mineral density (BMD) in Crohn's patients by 3 to 4 percent per year; addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial.
- Calcium and Vitamin D Most Effective for Treatment of Crohn's-related Bone Loss
Study shows that calcium and vitamin D treatment alone can improve bone mineral density (BMD) in Crohn's patients by 3 to 4 percent per year; addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial.
- Calcium and Vitamin D Most Effective for Treatment of Crohn's-related Bone Loss
Study shows that calcium and vitamin D treatment alone can improve bone mineral density (BMD) in Crohn's patients by 3 to 4 percent per year; addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial.
- Calcium and Vitamin D Most Effective for Treatment of Crohn's-related Bone Loss
Study shows that calcium and vitamin D treatment alone can improve bone mineral density (BMD) in Crohn's patients by 3 to 4 percent per year; addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial.
- Calcium and Vitamin D Most Effective for Treatment of Crohn's-related Bone Loss
Study shows that calcium and vitamin D treatment alone can improve bone mineral density (BMD) in Crohn's patients by 3 to 4 percent per year; addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial.
- Calcium and Vitamin D Most Effective for Treatment of Crohn's-related Bone Loss
Study shows that calcium and vitamin D treatment alone can improve bone mineral density (BMD) in Crohn's patients by 3 to 4 percent per year; addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial.
- U.S. Department of Defense University and Humanetics to Co-Develop Multiple Compounds
Focus of new agreement is to develop and commercialize nutritional supplements and drugs that show promise in supporting and protecting the immune system against challenges from exposure to radiation
- U.S. Department of Defense University and Humanetics to Co-Develop Multiple Compounds
Focus of new agreement is to develop and commercialize nutritional supplements and drugs that show promise in supporting and protecting the immune system against challenges from exposure to radiation
- Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort)
Researchers note that half of those given St. John's wort for six weeks in this randomised double blind, reference controlled trial, reported an improvement in their symptoms, versus one third of those who took Seroxat.
- Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort)
Researchers note that half of those given St. John's wort for six weeks in this randomised double blind, reference controlled trial, reported an improvement in their symptoms, versus one third of those who took Seroxat.
- Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort)
Researchers note that half of those given St. John's wort for six weeks in this randomised double blind, reference controlled trial, reported an improvement in their symptoms, versus one third of those who took Seroxat.
- Advitech Completes Recruitment For Second Clinical Study on Oral Treatment For Psoriasis
Eighty-four patients with mild to moderate psoriasis have been recruited; treatment phase is expected to be completed by the end of June and results should be made available in July.
- Advitech Completes Recruitment For Second Clinical Study on Oral Treatment For Psoriasis
Eighty-four patients with mild to moderate psoriasis have been recruited; treatment phase is expected to be completed by the end of June and results should be made available in July.
- Advitech Completes Recruitment For Second Clinical Study on Oral Treatment For Psoriasis
Eighty-four patients with mild to moderate psoriasis have been recruited; treatment phase is expected to be completed by the end of June and results should be made available in July.
- Advitech Completes Recruitment For Second Clinical Study on Oral Treatment For Psoriasis
Eighty-four patients with mild to moderate psoriasis have been recruited; treatment phase is expected to be completed by the end of June and results should be made available in July.
- New Chromium Supplementation Clinical Trial Initiated - First to Study Effects in Overweight Children with Type 1 Diabetes
Double-blind, randomized, placebo-controlled clinical trial to study the effects of chromium picolinate supplementation in overweight pediatric patients with poorly-controlled type 1 diabetes to be initiated at Childrens Hospital Los Angeles.
- New Chromium Supplementation Clinical Trial Initiated - First to Study Effects in Overweight Children with Type 1 Diabetes
Double-blind, randomized, placebo-controlled clinical trial to study the effects of chromium picolinate supplementation in overweight pediatric patients with poorly-controlled type 1 diabetes to be initiated at Childrens Hospital Los Angeles.
- New Chromium Supplementation Clinical Trial Initiated - First to Study Effects in Overweight Children with Type 1 Diabetes
Double-blind, randomized, placebo-controlled clinical trial to study the effects of chromium picolinate supplementation in overweight pediatric patients with poorly-controlled type 1 diabetes to be initiated at Childrens Hospital Los Angeles.
- New Chromium Supplementation Clinical Trial Initiated - First to Study Effects in Overweight Children with Type 1 Diabetes
Double-blind, randomized, placebo-controlled clinical trial to study the effects of chromium picolinate supplementation in overweight pediatric patients with poorly-controlled type 1 diabetes to be initiated at Childrens Hospital Los Angeles.
- New Chromium Supplementation Clinical Trial Initiated - First to Study Effects in Overweight Children with Type 1 Diabetes
Double-blind, randomized, placebo-controlled clinical trial to study the effects of chromium picolinate supplementation in overweight pediatric patients with poorly-controlled type 1 diabetes to be initiated at Childrens Hospital Los Angeles.
- St. John’s wort as Effective as Popular Prescription Anti-Depressant
Organization comments on study published Friday February 13th in British Medical Journal.
- St. John’s wort as Effective as Popular Prescription Anti-Depressant
Organization comments on study published Friday February 13th in British Medical Journal.
- 14-Center Study Confirms Effectiveness of Aller-7 in 545 People With Airborne Allergies
Multicenter clinical trial spanning three years and involving 545 patients in 14 clinical centers confirms the safety and efficacy of Aller-7(R) in people with allergic rhinitis.
- 14-Center Study Confirms Effectiveness of Aller-7 in 545 People With Airborne Allergies
Multicenter clinical trial spanning three years and involving 545 patients in 14 clinical centers confirms the safety and efficacy of Aller-7(R) in people with allergic rhinitis.
- 14-Center Study Confirms Effectiveness of Aller-7 in 545 People With Airborne Allergies
Multicenter clinical trial spanning three years and involving 545 patients in 14 clinical centers confirms the safety and efficacy of Aller-7(R) in people with allergic rhinitis.
- 14-Center Study Confirms Effectiveness of Aller-7 in 545 People With Airborne Allergies
Multicenter clinical trial spanning three years and involving 545 patients in 14 clinical centers confirms the safety and efficacy of Aller-7(R) in people with allergic rhinitis.
- Folic Acid May Prevent Hypertension in Addition to Reducing the Risk of Birth Defects
JAMA study shows that for younger women who consume at least 1000 micrograms of folic acid the incidence of hypertension is decrased by 46%.
- Folic Acid May Prevent Hypertension in Addition to Reducing the Risk of Birth Defects
JAMA study shows that for younger women who consume at least 1000 micrograms of folic acid the incidence of hypertension is decrased by 46%.
- Folic Acid May Prevent Hypertension in Addition to Reducing the Risk of Birth Defects
JAMA study shows that for younger women who consume at least 1000 micrograms of folic acid the incidence of hypertension is decrased by 46%.
- Folic Acid May Prevent Hypertension in Addition to Reducing the Risk of Birth Defects
JAMA study shows that for younger women who consume at least 1000 micrograms of folic acid the incidence of hypertension is decrased by 46%.
- Poor Prenatal Nutrition Permanently Damages Function of Insulin-producing Cells in the Pancreas
Mice studies indicate that poor prenatal nutrition impairs the pancreas's ability to later secrete enough insulin in response to blood glucose, leading to elevated risk of Type 2 diabetes later in life.
- Poor Prenatal Nutrition Permanently Damages Function of Insulin-producing Cells in the Pancreas
Mice studies indicate that poor prenatal nutrition impairs the pancreas's ability to later secrete enough insulin in response to blood glucose, leading to elevated risk of Type 2 diabetes later in life.
- Poor Prenatal Nutrition Permanently Damages Function of Insulin-producing Cells in the Pancreas
Mice studies indicate that poor prenatal nutrition impairs the pancreas's ability to later secrete enough insulin in response to blood glucose, leading to elevated risk of Type 2 diabetes later in life.
- Poor Prenatal Nutrition Permanently Damages Function of Insulin-producing Cells in the Pancreas
Mice studies indicate that poor prenatal nutrition impairs the pancreas's ability to later secrete enough insulin in response to blood glucose, leading to elevated risk of Type 2 diabetes later in life.
- Poor Prenatal Nutrition Permanently Damages Function of Insulin-producing Cells in the Pancreas
Mice studies indicate that poor prenatal nutrition impairs the pancreas's ability to later secrete enough insulin in response to blood glucose, leading to elevated risk of Type 2 diabetes later in life.
- Study Results Show Efficacy of Bioforce’s Prostasan
Swiss study of 364 men indicates reduction of symptoms.
- Study Results Show Efficacy of Bioforce’s Prostasan
Swiss study of 364 men indicates reduction of symptoms.
- Study Results Show Efficacy of Bioforce’s Prostasan
Swiss study of 364 men indicates reduction of symptoms.
- Study Results Show Efficacy of Bioforce’s Prostasan
Swiss study of 364 men indicates reduction of symptoms.
- Scientific Experts Meet to Discuss Safety and Benefits of Vitamin E
Group concluded that antioxidant supplements are safe and appear to confer a health benefit in certain individuals; Future research in well-defined populations with both clinical and biomarker end-points needs to be undertaken.
- Scientific Experts Meet to Discuss Safety and Benefits of Vitamin E
Group concluded that antioxidant supplements are safe and appear to confer a health benefit in certain individuals; Future research in well-defined populations with both clinical and biomarker end-points needs to be undertaken.
- Scientific Experts Meet to Discuss Safety and Benefits of Vitamin E
Group concluded that antioxidant supplements are safe and appear to confer a health benefit in certain individuals; Future research in well-defined populations with both clinical and biomarker end-points needs to be undertaken.
- Scientific Experts Meet to Discuss Safety and Benefits of Vitamin E
Group concluded that antioxidant supplements are safe and appear to confer a health benefit in certain individuals; Future research in well-defined populations with both clinical and biomarker end-points needs to be undertaken.
- Scientific Experts Meet to Discuss Safety and Benefits of Vitamin E
Group concluded that antioxidant supplements are safe and appear to confer a health benefit in certain individuals; Future research in well-defined populations with both clinical and biomarker end-points needs to be undertaken.
- Scientific Experts Meet to Discuss Safety and Benefits of Vitamin E
Group concluded that antioxidant supplements are safe and appear to confer a health benefit in certain individuals; Future research in well-defined populations with both clinical and biomarker end-points needs to be undertaken.
- COLD-fX(R) to be Studied as New Way to Protect Seniors from Influenza in Canadian Nursing Homes
Company announces partnership project
to investigate the potential use of COLD-fX(R) as a "standard of care" for the
prevention of upper respiratory infections in Canadian nursing homes.
- COLD-fX(R) to be Studied as New Way to Protect Seniors from Influenza in Canadian Nursing Homes
Company announces partnership project
to investigate the potential use of COLD-fX(R) as a "standard of care" for the
prevention of upper respiratory infections in Canadian nursing homes.
- COLD-fX(R) to be Studied as New Way to Protect Seniors from Influenza in Canadian Nursing Homes
Company announces partnership project
to investigate the potential use of COLD-fX(R) as a "standard of care" for the
prevention of upper respiratory infections in Canadian nursing homes.
- COLD-fX(R) to be Studied as New Way to Protect Seniors from Influenza in Canadian Nursing Homes
Company announces partnership project
to investigate the potential use of COLD-fX(R) as a "standard of care" for the
prevention of upper respiratory infections in Canadian nursing homes.
- New Study Shows GliSODin(R) Inhibits DNA Damage Due to Ischemia-reperfusion Induced Oxidative Stress
German researchers conclude that pretreatment with GliSODin inhibits oxidative DNA damage related to induced ischemia-reperfusion injury.
- New Study Shows GliSODin(R) Inhibits DNA Damage Due to Ischemia-reperfusion Induced Oxidative Stress
German researchers conclude that pretreatment with GliSODin inhibits oxidative DNA damage related to induced ischemia-reperfusion injury.
- New Study Shows GliSODin(R) Inhibits DNA Damage Due to Ischemia-reperfusion Induced Oxidative Stress
German researchers conclude that pretreatment with GliSODin inhibits oxidative DNA damage related to induced ischemia-reperfusion injury.
- New Study Shows GliSODin(R) Inhibits DNA Damage Due to Ischemia-reperfusion Induced Oxidative Stress
German researchers conclude that pretreatment with GliSODin inhibits oxidative DNA damage related to induced ischemia-reperfusion injury.
- Effect of Folate and Mecobalamin on Hip Fractures in Patients With Stroke
Study shows that folate and vitamin B12 reduce risk of hip fracture in elderly patients.
- Effect of Folate and Mecobalamin on Hip Fractures in Patients With Stroke
Study shows that folate and vitamin B12 reduce risk of hip fracture in elderly patients.
- Effect of Folate and Mecobalamin on Hip Fractures in Patients With Stroke
Study shows that folate and vitamin B12 reduce risk of hip fracture in elderly patients.
- Effect of Folate and Mecobalamin on Hip Fractures in Patients With Stroke
Study shows that folate and vitamin B12 reduce risk of hip fracture in elderly patients.
- Vitamin D Injections May Significantly Improve Survival in Dialysis Patients
Study to be published in the April Journal of the American Society of Nephrology, shows that 76% of those dialysis patients receiving any form of activated vitamin D were still alive at the end of a two-year period, compared with 59% of those not receiving the therapy; researchers suggest more studies.
- Vitamin D Injections May Significantly Improve Survival in Dialysis Patients
Study to be published in the April Journal of the American Society of Nephrology, shows that 76% of those dialysis patients receiving any form of activated vitamin D were still alive at the end of a two-year period, compared with 59% of those not receiving the therapy; researchers suggest more studies.
- Vitamin D Injections May Significantly Improve Survival in Dialysis Patients
Study to be published in the April Journal of the American Society of Nephrology, shows that 76% of those dialysis patients receiving any form of activated vitamin D were still alive at the end of a two-year period, compared with 59% of those not receiving the therapy; researchers suggest more studies.
- Vitamin D Injections May Significantly Improve Survival in Dialysis Patients
Study to be published in the April Journal of the American Society of Nephrology, shows that 76% of those dialysis patients receiving any form of activated vitamin D were still alive at the end of a two-year period, compared with 59% of those not receiving the therapy; researchers suggest more studies.
- Peer-Reviewed Published Study Demonstrates Safety of UC-II®
A recent study published in Toxicology Mechanisms and Methods demonstrates that UC-II®, InterHealth Nutraceuticals’ 40 mg, once-a-day, joint-health ingredient, is safe.
- Peer-Reviewed Published Study Demonstrates Safety of UC-II®
A recent study published in Toxicology Mechanisms and Methods demonstrates that UC-II®, InterHealth Nutraceuticals’ 40 mg, once-a-day, joint-health ingredient, is safe.
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- New Company for “Change-The-World” Entrepreneurs™ Launches
- GMP Labs Expands Liquid Nutraceutical Capabilities
- What Parents Should Know About Kids and Supplements
- What Parents Should Know About Kids and Supplements
- Oats Beat Back Cholesterol
- Oats Beat Back Cholesterol
- Seniors: Pump Up for Strong Bones and Heart
- Seniors: Pump Up for Strong Bones and Heart
|
QUEBEC, - February 21, 2005 – (TSX-V: AVI) Canadian biotech company Advitech and the CHUL Research Center, CHULRC (CHUQ) will carry out a research project to assess the potential of XP-828L for treatment of inflammatory bowel diseases. XP-828L is Advitech’s main platform. It is a purified milk protein fraction with a patented growth factor composition.
The in vivo study, which will be conducted by Dr Patrice E. Poubelle, researcher at the CHULRC, will use a recognized animal model of chronic inflammatory diseases, the HLA-B27T transgenic rats model. Inflammatory bowel diseases affect close to 1% of the population. The causes are not entirely known, but researchers are now better able to understand the action of the immune system at the onset of the disease.
“This project represents an important extension of our XP-828L platform, in view of the significant market opportunities involved,” mentioned Renaud Beauchesne, Advitech’s President and Chief Executive Officer. “We are also extremely happy to be associated with the CHUL Research Centre, given the role it plays in medical research in Canada and the expertise of its researchers, especially with regard to chronic inflammatory diseases”.
“Advitech’s project is of great interest, since it will make it possible to validate new therapeutic indications for complex diseases such as granulomatous colitis or better known as Crohn’s disease,” stated Dr. Patrice E. Poubelle, researcher at the CHUL Research Center and Advitech’s special scientific advisor. “Patients suffering from those chronic inflammatory diseases often experience extremely difficult life constraints as a result of their disease. The available treatments are often linked to various side effects, that can be severe. Advitech’s technology could be a useful therapeutic alternative in that regard, especially because of the safety profile which appears favourable, according to a recent open study”.
This study should be completed by the end of the second quarter of 2005. The results should be made available during the third quarter. Based on the results, a first clinical trial on patients suffering from inflammatory bowel diseases could be undertaken in 2006.
XP-828L was already the subject of a first clinical trial in 2004 for the treatment of psoriasis, a chronic inflammatory skin disease. A second clinical study for psoriasis is currently in process.
About Advitech
Advitech is a biotechnology company specializing in the development of bioactive ingredients from dairy proteins. Its key focus areas are in the fields of immunology and inflammation. Its main platform, XP-828L, is a growth factor complex used as an oral product for mild to moderate psoriasis and also for other immune-mediated chronic inflammatory diseases. Advitech’s common shares are listed on the TSX Venture Exchange under the symbol AVI. The number of common shares outstanding is 54,799,818.
- 30 -
This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The reader is cautioned not to rely on these forward-looking statements.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Michel Lamontagne, MBA
Vice President and Chief Financial Officer
(418) 686-7498 ext. 237
m.lamontagne@advitech.com |